Eli Lilly (LLY) earnings Q1 2024

Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020. 

Mike Blake | Reuters

Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street’s expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss treatment Zepbound.

The drugmaker now expects full-year adjusted earnings of $13.50 to $14.00 per share, up from previous guidance of $12.20 to $12.70 per share. Eli Lilly also expects revenue for the year to come in between $42.4 billion and $43.6 billion, an increase of $2 billion at either end of the range.

Analysts surveyed by LSEG expected full-year adjusted earnings of $12.50 per share and sales of $41.44 billion. 

The company said the boosted guidance is in part due to optimism around increased production of Zepbound, Mounjaro and similar drugs for the rest of the year.

“Now that we’re four months into the year, we have greater visibility into that, into these nodes of capacity and feel more confident,” Eli Lilly CFO Anat Ashkenazi told investors during an earnings call Tuesday.

She noted that Eli Lilly has several manufacturing sites either “ramping up or under construction,” including two locations in North Carolina, two in Indiana, one in Ireland and one in Germany, along with a seventh site the company recently acquired from Nexus Pharmaceuticals.

Eli Lilly said demand for Mounjaro and Zepbound — treatments known as incretin drugs, which mimic hormones produced in the gut to suppress a person’s appetite and regulate their blood sugar — outpaced increases in supply during the quarter. And the company expects supply to remain “quite tight” in the near- to mid-term amid continued demand for those drugs, Ashkenazi said.

But Eli Lilly expects the most significant production increases expected in the second half of the year, she noted.

“Our top priority is making more product, and we’re doing everything we can to do that,” Eli Lilly CEO David Ricks said in an interview Tuesday on CNBC’s “Squawk Box.” “We’re ramping that aggressively. But it’s capital intensive, it’s technically complex and highly regulated.”

The results and guidance raise reflect Zepbound’s first full quarter on the U.S. market after winning approval from regulators in early November. The drug reported $517.4 million in sales for the first quarter, even as most doses of the drug slipped into shortages in the U.S. that are expected to last through June.

Analysts say the weekly injection could post more than a billion dollars in sales in its first year on the market and potentially become the biggest drug of all time.

Here’s what Eli Lilly reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

  • Earnings per share: $2.58 adjusted vs. $2.46 expected
  • Revenue: $8.77 billion vs. $8.92 billion expected

Eli Lilly posted net income of $2.24 billion, or $2.48 a share, for the first quarter. That compares with a profit of $1.34 billion, or $1.49 a share, a year earlier. 

Excluding one-time items associated with the value of intangible assets, among other adjustments, the company posted a per-share profit of $2.58 for the first quarter of 2024.

The pharmaceutical giant booked first-quarter revenue of $8.77 billion, up 26% year over year.

Shares of Eli Lilly jumped more than 5% on Tuesday. The stock is up 26% this year after surging almost 60% in 2023 due to the insatiable demand for the company’s weight loss and diabetes drugs. That’s despite their hefty price tags, spotty insurance coverage and intermittent supply shortages. 

With a market cap of about $700 billion, Eli Lilly is the largest pharmaceutical company based in the U.S. 

Mounjaro, Trulicity results

Other drugs miss expectations

Source link

Related Posts

2025 Valentine’s Day Gifts Ideas (That Beat Chocolate and Flowers!)

I know I might sound unromantic, but something in me rebels against commercialized holidays (like Valentine’s Day). You won’t find me buying heart-shaped boxes of candy or flowers that will…

Read more

Hibiscus Rose Herbal Marshmallows

Marshmallows are always a big hit in our household. Years ago I created my basic marshmallow recipe (with optional probiotics!) and I’ve done a few spin-offs from there. This rose…

Read more

Creamy Buffalo Chicken Dip: The Perfect High-Protein Snack or Meal

Once upon a time, I invested in a cottage cheese brand because it was delicious and reminded me of my childhood. I’m still grateful to this day that I did…

Read more

My 2025 Wellness Trend Predictions

It seems like with each year and generation new trends come rolling around. Often they’re just a rehash of old trends (nothing new under the sun…). In today’s post, I’m…

Read more

Sweet Salt Texturizing Spray for Hair

Finding natural hair care products that work can be a challenge. I’ve shared my natural hair spray recipe and my beach waves sea salt spray before. I like both of…

Read more

Tangy Greek Salad Dressing

Once upon a time in Belgium, I went to an amazing Greek restaurant. What does that have to do with salad dressing you may ask? I’m a firm believer in…

Read more

Leave a Reply